GB2347742B - Pharmaceutical composition for RBD - Google Patents

Pharmaceutical composition for RBD

Info

Publication number
GB2347742B
GB2347742B GB9928642A GB9928642A GB2347742B GB 2347742 B GB2347742 B GB 2347742B GB 9928642 A GB9928642 A GB 9928642A GB 9928642 A GB9928642 A GB 9928642A GB 2347742 B GB2347742 B GB 2347742B
Authority
GB
United Kingdom
Prior art keywords
rbd
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9928642A
Other versions
GB9928642D0 (en
GB2347742A (en
Inventor
Andrew Jeremy Wakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Free Hospital School of Medicine
Original Assignee
Royal Free Hospital School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9711663.6A priority Critical patent/GB9711663D0/en
Priority claimed from GBGB9711663.6A external-priority patent/GB9711663D0/en
Application filed by Royal Free Hospital School of Medicine filed Critical Royal Free Hospital School of Medicine
Priority claimed from GB9926916A external-priority patent/GB2341551A/en
Publication of GB9928642D0 publication Critical patent/GB9928642D0/en
Publication of GB2347742A publication Critical patent/GB2347742A/en
Application granted granted Critical
Publication of GB2347742B publication Critical patent/GB2347742B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB9928642A 1997-06-05 1998-06-04 Pharmaceutical composition for RBD Expired - Fee Related GB2347742B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9711663.6A GB9711663D0 (en) 1997-06-05 1997-06-05 Pharmaceutical composition for treatment of IBD and RBD

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711663.6A GB9711663D0 (en) 1997-06-05 1997-06-05 Pharmaceutical composition for treatment of IBD and RBD
GB9926916A GB2341551A (en) 1997-06-05 1998-06-04 Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder

Publications (3)

Publication Number Publication Date
GB9928642D0 GB9928642D0 (en) 2000-02-02
GB2347742A GB2347742A (en) 2000-09-13
GB2347742B true GB2347742B (en) 2001-11-07

Family

ID=26311660

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9928642A Expired - Fee Related GB2347742B (en) 1997-06-05 1998-06-04 Pharmaceutical composition for RBD

Country Status (1)

Country Link
GB (1) GB2347742B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105664144B (en) 2009-01-06 2020-08-11 加尔纳根有限责任公司 Compositions and methods for treating or preventing staphylococcus aureus infections and eradicating or reducing staphylococcus aureus on surfaces
JP2012514604A (en) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for the treatment or prevention of oral infection by E. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
BR112013027034A8 (en) 2011-04-21 2018-01-02 Curemark Llc "compounds for the treatment of neuropsychiatric disorders."
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101200A2 (en) * 1982-07-20 1984-02-22 BIO-COM Inc. Transfer factor for use in treating viral infections
WO1996030544A1 (en) * 1995-03-28 1996-10-03 Andrew Jeremy Wakefield Diagnostic and therapeutic system for crohn's disease and colitia ulcerosa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101200A2 (en) * 1982-07-20 1984-02-22 BIO-COM Inc. Transfer factor for use in treating viral infections
WO1996030544A1 (en) * 1995-03-28 1996-10-03 Andrew Jeremy Wakefield Diagnostic and therapeutic system for crohn's disease and colitia ulcerosa
GB2300259A (en) * 1995-03-28 1996-10-30 Andrew Jeremy Wakefield Diagnosing Crohn's disease or ulcerative colitis by detection of measles virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Clin. Microbiol. Vol. 31 (3) 1991. Condorelli F & ZieglerT pages 717-719 *
J. Virol. Methods Vol. 15 1987. Fukuda A et.al. pages 279-284 *
J. Virol. Methods Vol. 27 1990. Umino Y et.al. pages 159-168 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders

Also Published As

Publication number Publication date
GB9928642D0 (en) 2000-02-02
GB2347742A (en) 2000-09-13

Similar Documents

Publication Publication Date Title
GB9706089D0 (en) Pharmaceutical composition
GB9727053D0 (en) Pharmaceutical compositions
PT1466615E (en) Pharmaceutical composition
CY2569B1 (en) Pharmaceutical compositions
GB2347742B (en) Pharmaceutical composition for RBD
PL343769A1 (en) Pharmaceutical composition
EP0978288A4 (en) Medicinal composition
GB9818591D0 (en) Pharmaceutical composition
IL133928A0 (en) Pharmaceutical composition containing peptichemio
GB9717444D0 (en) Pharmaceutical composition
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
GB9717428D0 (en) Pharmaceutical composition
GB9723985D0 (en) Pharmaceutical compositions
GB9726735D0 (en) Pharmaceutical compositions
IL122920A (en) Castrointestinal drug composition
HK1044117B (en) Pharmaceutical composition
HU9700632D0 (en) Pharmaceutical compositions
GB9717770D0 (en) Pharmaceutical composition
GB2321190B (en) Pharmaceutical composition
ZA982117B (en) Pharmaceutical compositions
GB9726781D0 (en) Pharmaceutical composition
HU9800078D0 (en) Pharmaceutical composition
ZA981391B (en) Pharmaceutical composition
HU9701598D0 (en) Pharmaceutical composition
GB9712097D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20080604